Celyad Oncology SA
CLYYF
$0.25
-$0.10-28.57%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.10K | 4.10K | 7.90K | 7.40K | 91.70K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.10K | 4.10K | 7.90K | 7.40K | 91.70K |
| Cost of Revenue | 0.00 | 0.00 | 4.50K | 4.20K | 1.60K |
| Gross Profit | 4.10K | 4.10K | 3.40K | 3.20K | 90.10K |
| SG&A Expenses | 1.22M | 1.23M | 952.80K | 883.40K | 778.70K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -3.29M | -3.31M | -55.00K | -51.00K | -109.30K |
| Total Operating Expenses | -1.29M | -1.30M | 2.08M | 1.93M | 1.58M |
| Operating Income | 1.30M | 1.30M | -2.07M | -1.92M | -1.48M |
| Income Before Tax | 2.62M | 2.63M | -2.09M | -1.93M | -1.48M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 2.62M | 2.63M | -2.09M | -1.93M | -1.48M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.62M | 2.63M | -2.09M | -1.93M | -1.48M |
| EBIT | 1.30M | 1.30M | -2.07M | -1.92M | -1.48M |
| EBITDA | 1.30M | 1.34M | -1.96M | -1.82M | -1.44M |
| EPS Basic | 0.06 | 0.06 | -0.05 | -0.05 | -0.04 |
| Normalized Basic EPS | 0.02 | 0.02 | -0.03 | -0.03 | -0.02 |
| EPS Diluted | 0.05 | 0.05 | -0.05 | -0.05 | -0.04 |
| Normalized Diluted EPS | 0.02 | 0.02 | -0.03 | -0.03 | -0.02 |
| Average Basic Shares Outstanding | 44.13M | 44.13M | 41.43M | 41.43M | 41.43M |
| Average Diluted Shares Outstanding | 51.11M | 51.11M | 41.43M | 41.43M | 41.43M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |